A high-throughput drug screening study that has recently been conducted by utilizing the survival of ALS patient iMNs as readout has identified bosutinib, the Src/c-Abl inhibitor approved by FDA for treating patients with chronic myelogenous leukemia, as a potential therapeutic candidate for ALS (Imamura et al., 2017). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.